Navigation Links
Novelos Therapeutics And Academic Collaborators Present Three Posters At 2012 World Molecular Imaging Congress
Date:9/7/2012

ter Phase 2 trials in the third quarter of 2013 as a monotherapy for solid tumors with significant unmet medical need, subject to additional funding.  CLR1502 (GLOW2) is a preclinical cancer-targeted optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging.  Together, we believe our compounds are able to "find, treat and follow" cancer anywhere in the body in a novel, effective and highly selective way.  For additional information please visit www.novelos.com.

This news release contains forward-looking statements.  You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate," "intend," "could," "estimate," "continue," "plans," or their negatives or cognates.  Such statements are valid only as of today, and we disclaim any obligation to update this information.  These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.  These statements are based on our current beliefs and expectations as to such future outcomes.  Drug discovery and development involve a high degree of risk.  Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our  pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement.

INVESTOR CONTACTS
J. Patrick Genn, Vice President of IR, Novelos Therapeutics, Inc., Madison, Wisc. & Boston, Mass., P
'/>"/>

SOURCE Novelos Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. Novelos Therapeutics Prices $5.4 Million Public Offering
4. Novelos Therapeutics to Present at LHA Life Sciences & Medical Technologies Virtual Conference on June 28
5. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
6. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
7. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
8. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
9. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... ANGELES , Sept. 30, 2014 ... biopharmaceutical research and development company specializing in oncology, ... 2b clinical trial evaluating aldoxorubicin compared to topotecan ... (SCLC) who have relapsed or were refractory to ... the widely-used chemotherapeutic agent, doxorubicin. CytRx has received ...
(Date:9/29/2014)... et SAN DIEGO ... Company, Ltd. (ci-après désignée Daiichi Sankyo) (TSE : 4568) ... aujourd,hui la conclusion d,un accord de fusion définitif ... la totalité des actions ordinaires en circulation d,Ambit ... par le biais d,une offre publique d,achat qui ...
(Date:9/29/2014)... Sept. 29, 2014  Bob Pack, who lost his ... on the California Medical Association to immediately cease airing ... the San Jose Mercury News called "shamelessly deceptive" and ... wants voters to believe about the measure is wrong." ... Prop 46 requirement that doctors check California,s ...
Breaking Medicine Technology:CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 2Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 3Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 4Father Calls On CA Medical Assn To Pull TV Ad Called "Jaw-Droppingly Deceptive" and "Baloney" By LA Times & "Shamelessly Deceptive" By San Jose Mercury News, Says Consumer Watchdog Campaign 5
(Date:9/30/2014)... 30, 2014 Youth Town’s annual BBQ/Music ... a.m. to 2 p.m. at the Youth Town campus ... World sponsors this family-oriented festival, which will offer music, ... will feature a car show, arts and crafts fair, ... children’s games. Also, Lightning McQueen and Mater from the ...
(Date:9/30/2014)... 30, 2014 Signet Puerto Rico, ... in San Juan, Puerto Rico, leverages RamSoft’s PowerServer ... , Nivia Souffront, site Administrator for Signet Puerto ... are excited to bring in PowerServer RIS/PACS/PM because ... care and physician satisfaction while reducing our costs ...
(Date:9/30/2014)... 30, 2014 Named a ‘Post ... Longmeadow facility has officially announced that they will ... that combines advanced medical technology with supportive, personalized ... of the only non-hospital options available in the ... The primary focus of this Ventilator Program is ...
(Date:9/30/2014)... 2014 Seniors Guide will take part ... race beginning in Raleigh, to support Alzheimer’s North Carolina ... and care. , Associate Publisher of Seniors Guide Magazine, ... senior resource for the Raleigh-Durham-Chapel Hill areas of North ... will be helping their team, “Eye of the Tiger”, ...
(Date:9/30/2014)... Employment website iHire ( http://www.ihire.com ) ... its marketing group, adding an experienced professional to ... their hiring needs within all of iHire’s niche ... sales and business development roles in traditional, digital, ... advertising. , With a wide-ranging career that has ...
Breaking Medicine News(10 mins):Health News:Signet Puerto Rico Leverages PowerServer RIS/PACS/PM™ to Improve Patient Care, Cut Costs 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 2Health News:Wingate Healthcare Announces New Ventilator Care Program at East Longmeadow Facility 3Health News:Seniors Guide To Run in 203 Mile Alzheimer’s Awareness Relay in Raleigh, North Carolina 2Health News:Seniors Guide To Run in 203 Mile Alzheimer’s Awareness Relay in Raleigh, North Carolina 3Health News:iHire Expands Team With New Business Development Director 2
... Many of ... water scarcity have steep energy costs. , ... (PRWEB) June 17, 2010 -- This June award winning publication, IEEE Spectrum features ... water. According to a new special report in IEEE Spectrum magazine, the flagship monthly publication ...
... ... announce the addition of Lázaro Garza as an Engineered Sales Representative for Ellsworth Adhesives S. ... ... the addition of Lázaro Garza as an Engineered Sales Representative for Ellsworth Adhesives S. de ...
... is a great deal of interest in factors that contribute ... One factor that appears to contribute to the heritable ... codes for the serotonin transporter, also known as the serotonin ... transporter gene appears to increase one,s risk for depression and ...
... BOSTON (June 17, 2010) - Staying in shape may ... those with higher than desirable body fat percentages. In ... Nutrition Science and Policy at Tufts University found an ... metabolic risk factors that are precursors to cardiovascular disease ...
... ... like driving, especially those parents who live in areas where public transportation is limited or ... group in Walnut Creek and San Francisco to cope with this and many other dilemmas. ... Walnut Creek, CA (PRWEB) ...
... cancer treatment more likely to have variant, study shows ... identified a gene mutation that increases the risk of ... after surgery for early-stage breast cancer. , Tamoxifen is ... but previous studies have shown that it increases the ...
Cached Medicine News:Health News:Green Energy May Drain Our Water Supplies 2Health News:Green Energy May Drain Our Water Supplies 3Health News:Ellsworth Adhesives Announces New International Engineered Sales Representative 2Health News:PTSD: The serotonin system influences vulnerability and treatment 2Health News:Physical fitness may help reduce chronic disease risk in college students 2Health News:Support Group for Families Dealing with When to Take the Keys Away From Dad and Other Issues 2Health News:Support Group for Families Dealing with When to Take the Keys Away From Dad and Other Issues 3Health News:Support Group for Families Dealing with When to Take the Keys Away From Dad and Other Issues 4Health News:Gene Mutation Offers Clues to Tamoxifen-Blood Clot Link 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: